NEWRON PHARMACEUT. EO-20 (F:NP5) — Market Cap & Net Worth
Market Cap & Net Worth: NEWRON PHARMACEUT. EO-20 (NP5)
NEWRON PHARMACEUT. EO-20 (F:NP5) has a market capitalization of $300.40 Million (€256.95 Million) as of July 22, 2026. Listed on the F stock exchange, this Germany-based company holds position #14647 globally and #1471 in its home market, demonstrating a -2.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NEWRON PHARMACEUT. EO-20's stock price €12.35 by its total outstanding shares 20805797 (20.81 Million). See NP5 capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
NEWRON PHARMACEUT. EO-20 Market Cap History: 2015 to 2026
NEWRON PHARMACEUT. EO-20's market capitalization history from 2015 to 2026. Data shows change from $559.46 Million to $300.40 Million (-5.62% CAGR).
NEWRON PHARMACEUT. EO-20 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NEWRON PHARMACEUT. EO-20's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
33.89x
NEWRON PHARMACEUT. EO-20's market cap is 33.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $36.53 Million | $5.76 Million | -$14.90 Million | 6.34x | N/A |
| 2022 | $35.76 Million | $6.09 Million | -$17.49 Million | 5.87x | N/A |
| 2023 | $136.22 Million | $9.06 Million | -$16.22 Million | 15.04x | N/A |
| 2024 | $225.97 Million | $51.39 Million | $15.84 Million | 4.40x | 14.26x |
| 2025 | $648.24 Million | $19.13 Million | -$13.24 Million | 33.89x | N/A |
Competitor Companies of NP5 by Market Capitalization
Companies near NEWRON PHARMACEUT. EO-20 in the global market cap rankings as of July 22, 2026.
Key companies related to NEWRON PHARMACEUT. EO-20 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #560 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $480.50 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $672.15 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €753.60 |
| #560 | UCB SA | BR:UCB | $47.34 Billion | €238.00 |
NEWRON PHARMACEUT. EO-20 Historical Marketcap From 2015 to 2026
Between 2015 and today, NEWRON PHARMACEUT. EO-20's market cap moved from $559.46 Million to $ 300.40 Million, with a yearly change of -5.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €300.40 Million | -53.66% |
| 2025 | €648.24 Million | +186.87% |
| 2024 | €225.97 Million | +65.89% |
| 2023 | €136.22 Million | +280.95% |
| 2022 | €35.76 Million | -2.13% |
| 2021 | €36.53 Million | -21.44% |
| 2020 | €46.51 Million | -66.46% |
| 2019 | €138.65 Million | -75.22% |
| 2018 | €559.46 Million | 0.00% |
| 2017 | €559.46 Million | 0.00% |
| 2016 | €559.46 Million | 0.00% |
| 2015 | €559.46 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of NEWRON PHARMACEUT. EO-20 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $300.40 Million USD |
| MoneyControl | $300.40 Million USD |
| MarketWatch | $300.40 Million USD |
| marketcap.company | $300.40 Million USD |
| Reuters | $300.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more